Cyclosporin-Induced Remission of IDDM After Early Intervention: Association of 1 yr of Cyclosporin Treatment With Enhanced Insulin Secretion

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Diabetes

• Publication date

  1988-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/diab.37.11.1574PMID 2903105
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of immunosuppression with cyclosporine in insulin-dependent diabetes mellitus of recent onset: the Canadian open study at 44 months.

  1988cited by this paper
• Mechanism of action: ciclosporin- and prolactin-mediated control of immunity.

  1986cited by this paper
• Direct Effects of Cyclosporin A on Human Pancreatic β-cells

  1986cited by this paper
• Mechanisms of Pancreatic Islet Cell Destruction Dose‐Dependent Cytotoxic Effect of Soluble Blood Mononuclear Cell Mediators on Isolated Islets of Langerhans

  1986cited by this paper
• Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.

  1986cited by this paper
• Natural course of insulin resistance in type I diabetes.

  1986cited by this paper
• Ciclosporin-associated Nephropathy

  1985cited by this paper
• Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus.

  1985cited by this paper
• Type I Diabetes Mellitus: Rationale for Immune Intervention

  1985cited by this paper
• The Mechanism of Action of Ciclosporin: A Continuing Puzzle

  1985cited by this paper
• Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.

  1984cited by this paper
• Type I diabetes mellitus in monozygotic twins: chronic progressive beta cell dysfunction.

  1983cited by this paper
• Cyclosporine: action, pharmacokinetics, and effect in the BB rat model.

  1983cited by this paper
• Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus.

  1981cited by this paper
• Improved colorimetric assay for glycosylated hemoglobin.

  1981cited by this paper

• Immunotherapies for prevention and treatment of type 1 diabetes

  2025cites this paper
• Historically Based Perspective on the Immunotherapy of Type 1 Diabetes: Where We Have Been, Where We Are, and Where We May Go

  2025cites this paper
• Efficacy of immunosuppression in preserving beta cell function and reducing insulin requirements in Type 1 diabetes mellitus: a comprehensive review

  2025cites this paper
• The Teplizumab Saga: The Challenge of Not Getting Lost in Clinical Translation.

  2024cites this paper
• Multifaceted nature of young-onset diabetes - can genomic medicine improve the precision of diagnosis and management?

  2024cites this paper
• Identifying Promising Immunomodulators for Type 1 Diabetes (T1D) and Islet Transplantation

  2024cites this paper
• Type 1 diabetes: what is the role of autoimmunity in β cell death?

  2022cites this paper
• GDF15: a potential therapeutic target for type 1 diabetes

  2022cites this paper
• CCL21 and beta-cell antigen releasing hydrogels as tolerance-inducing therapy in Type I diabetes.

  2022cites this paper
• Novel Insights into the Immunotherapy-Based Treatment Strategy for Autoimmune Type 1 Diabetes

  2022cites this paper
• Encapsulation Strategies for Pancreatic Islet Transplantation without Immune Suppression

  2021cites this paper
• Etiology of Autoimmune Islet Disease: Timing Is Everything

  2021cites this paper
• B Quiet: Autoantigen-Specific Strategies to Silence Raucous B Lymphocytes and Halt Cross-Talk with T Cells in Type 1 Diabetes

  2021cites this paper
• Prevention of Autoimmune Disease: The Type 1 Diabetes Paradigm

  2020cites this paper
• Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study

  2020cites this paper
• A future for CD3 antibodies in immunotherapy of type 1 diabetes

  2019cites this paper
• Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives

  2019cites this paper
• CD4/CD8 Antibodies Reduce Histopathological Damage in Salivary Glands of Spontaneously Diabetic Mice

  2019cites this paper
• Combination Immunotherapy for Type 1 Diabetes

  2017cites this paper
• Immunotherapy for Type 1 Diabetes: Why Do Current Protocols Not Halt the Underlying Disease Process?

  2017cites this paper
• Regulatory T cell therapy for type 1 diabetes: May the force be with you.

  2016cites this paper
• Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial

  2016cites this paper
• Concise Review: Cell‐Based Therapies and Other Non‐Traditional Approaches for Type 1 Diabetes

  2016cites this paper
• Immunoablation and autologous hematopoietic stem cell transplantation in the treatment of new-onset type 1 diabetes mellitus: long-term observations

  2016cites this paper
• Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus

  2016cites this paper
• Regulatory T cell therapy for type 1 diabetes: May the force be with you Journal of Autoimmunity

  2016cites this paper
• Étiologie et physiopathologie du diabète de type 1

  2016cites this paper
• Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes

  2016cites this paper
• Therapeutic potential of umbilical cord blood cells for type 1 diabetes mellitus

  2015cites this paper
• Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?

  2015cites this paper
• Comparison of Metabolic Outcomes in Children Diagnosed with Type 1 Diabetes Through Research Screening (Diabetes Autoimmunity Study in the Young [DAISY]) Versus in the Community

  2015cites this paper
• Prevention and Reversal of Type 1 Diabetes—Past Challenges and Future Opportunities

  2015cites this paper
• Prevention and Reversal of Type 1 Diabetes d Past Challenges and Future Opportunities

  2015cites this paper
• GAD‐treatment of children and adolescents with recent‐onset type 1 diabetes preserves residual insulin secretion after 30 months

  2014cites this paper
• Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case

  2014cites this paper
• What is the role of autoimmunity in type 1 diabetes? A clinical perspective

  2014cites this paper
• Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?

  2014cites this paper
• Type 1 diabetes.

  2013cites this paper
• Type 1 diabetes in children

  2013cites this paper
• C-peptide in diabetes diagnosis and therapy.

  2013cites this paper
• Cell‐based interventions to halt autoimmunity in type 1 diabetes mellitus

  2013cites this paper
• Immunology of Type I Diabetes: The Journey from Animal Models to Human Therapeutics

  2013cites this paper
• DIABETIC STUDIES The Review of Chapter III . 4 Clinical Potential of Antigen-Specific Therapies in Type 1 Diabetes

  2013cites this paper
• Antigen-based vs. systemic immunomodulation in type 1 diabetes

  2013cites this paper
• Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.

  2013cites this paper
• Trials in type 1 diabetes: Antigen-specific therapies.

  2013cites this paper
• Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents.

  2013cites this paper
• Immunotherapy Trials for Type 1 Diabetes: The Contribution of George Eisenbarth

  2013cites this paper
• GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.

  2012cites this paper
• Novel therapy for type 1 diabetes: Autologous hematopoietic stem cell transplantation

  2012cites this paper
• Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children

  2012cites this paper
• Recent Lessons Learned From Prevention and Recent-Onset Type 1 Diabetes Immunotherapy Trials

  2012cites this paper
• Clinical potential of antigen-specific therapies in type 1 diabetes.

  2012cites this paper
• Pathophysiology of Diabetes

  2012cites this paper
• Immunotherapy in autoimmune type 1 diabetes.

  2012cites this paper
• Pharmacoeconomics of Diabetes Surveillance and Detection Programmes

  2012cites this paper
• DB120562 9..17

  2012cites this paper
• Clinical immunologic interventions for the treatment of type 1 diabetes.

  2012cites this paper
• Making progress: preserving beta cells in type 1 diabetes

  2011cites this paper
• Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.

  2011cites this paper
• Residual Beta Cell Function in Newly Diagnosed Type 1 Diabetes after Treatment with Atorvastatin: The Randomized DIATOR Trial

  2011cites this paper
• Noninsulin pharmacological management of type 1 diabetes mellitus

  2011cites this paper
• Editorial Comment on type 1 diabetes and antigen‐specific immunotherapy

  2011cites this paper
• Vaccination against type 1 diabetes

  2011cites this paper
• What causes type 1 diabetes? Lessons from animal models

  2011cites this paper
• Prevention of type 1 diabetes.

  2011cites this paper
• A historical view from thirty eventful years of immunotherapy in autoimmune diabetes.

  2011cites this paper
• Does immune-tolerance treatment with Alum-formulated GAD65 protect insulin-production in the pancreatic islet β cells?

  2011cites this paper
• Ingested Type I Interferon—State of the Art as Treatment for Autoimmunity Part 2

  2010cites this paper
• Роль цитокинов в патогенезе аутоиммунного диабета,

  2010cites this paper
• Blockade of interleukin 1 in type 1 diabetes mellitus

  2010cites this paper
• Clinical applications of diabetes antibody testing.

  2010cites this paper
• Current Advances and Travails in Islet Transplantation

  2009cites this paper
• C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.

  2009cites this paper
• Immunotherapy for the Prevention and Treatment of Type 1 Diabetes

  2009cites this paper
• Strategies to prevent type 1 diabetes

  2009cites this paper
• Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials

  2009cites this paper
• Therapeutic approaches based on beta-cell mass preservation and/or regeneration.

  2009cites this paper
• In vitro (re)programming of human bone marrow stromal cells toward insulin‐producing phenotypes

  2009cites this paper
• Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.

  2009cites this paper
• C‐peptide in the natural history of type 1 diabetes

  2009cites this paper
• Six Months of Diazoxide Treatment at Bedtime in Newly Diagnosed Subjects With Type 1 Diabetes Does Not Influence Parameters of β-Cell Function and Autoimmunity but Improves Glycemic Control

  2009cites this paper
• Prevention of type 1 diabetes.

  2009cites this paper
• The road not taken: A path to curing type 1 diabetes?

  2009cites this paper
• Effect of Ingested Interferon-α on β-Cell Function in Children With New-Onset Type 1 Diabetes

  2009cites this paper
• Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.

  2009cites this paper
• Counterpoint: Clinical Islet Transplantation: Not Ready for Prime Time

  2009cites this paper
• Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization

  2008cites this paper
• Type 1 Diabetes TrialNet–An International Collaborative Clinical Trials Network

  2008cites this paper
• Immunotherapeutic agents in type 1 diabetes: a systematic review and meta‐analysis of randomized trials

  2008cites this paper
• Stopping diabetes in its tracks: autologous non-myeloablative stem cell transplantation.

  2007cites this paper
• [Diabetic ketoacidosis responsive to methotrexate in a patient with a mixed connective tissue disease].

  2007cites this paper
• Prediction and Prevention of Type 1 Diabetes: Progress, Problems, and Prospects

  2007cites this paper
• MellitusTransplantation in Newly Diagnosed Type 1 Diabetes Autologous Nonmyeloablative Hematopoietic Stem Cell

  2007cites this paper
• Trasplante de clulas madre hematopoyticas en la diabetes tipo 1

  2007cites this paper
• Association of immune mediators at diagnosis of Type 1 diabetes with later clinical remission

  2007cites this paper
• Effect of heat shock protein peptide DiaPep277 on ß‐cell function in paediatric and adult patients with recent‐onset diabetes mellitus type 1: two prospective, randomized, double‐blind phase II trials

  2007cites this paper
• Stem cell-based therapy for the treatment of Type 1 diabetes mellitus.

  2007cites this paper
• Insulin treatment and type 1 diabetes topics.

  2006cites this paper
• Antigen-based prediction and prevention of type 1 diabetes.

  2006cites this paper